QbD Pharmaceutical is a research-driven company, with its core competitiveness being the "QbD" international R&D model that meets the requirements of China, the US, and Europe. This model can achieve a R&D efficiency that is more than 40% higher than that of most domestic companies, and the optimal process can be inferred from experimental design (DoE) using data, rather than through continuous optimization based on experience. The data is more scientific and persuasive.     QbD  Pharmaceutical follows the "two-eight" principle, with eight being R&D and two being production. The company's product portfolio focuses on acute rescue drugs, with more than 15 proprietary API and 20 proprietary formulations being successively filed for market approval each year. The company's product launch criteria include three aspects: first, drugs with differences between the US, Europe, and China; second, drugs that meet the "small, new, and special" criteria, have a certain market size, and have API or formulation technological barriers; and third, complex injectables with technical feasibility. 

The industrial layout of QbD Pharmaceutical is: The company's products are focused on emergency drugs, contrast agents, and anesthetics. We own the rights to "small new special" raw materials and formulations; large-scale ton-level raw materials are entrusted to Hebei Baiyishikong Pharmaceutical Industry Co., Ltd. for production on a large scale, with exclusive operation; for formulations with technical barriers that cannot be entrusted for production, they are produced in-house, and those that can be entrusted are entrusted based on scale, with large-scale entrustment to Shanxi Pu'er Pharmaceutical Industry Co., Ltd. and small-scale entrustment to Hebei Kaiwei Pharmaceutical Co., Ltd. The company's industrial advantages are reflected in three aspects: First, the "small new special" raw materials with technical barriers, which guarantee the completeness and safety of the product chain; second, the pre-filled syringe production line integrating the blister packaging bottle, pre-filled syringe, and injection pen, of which the injection pen is the first in China; third, the unique freeze-dried tablets, with half of the oral disintegrating tablets being obtained by freeze-drying technology, which is currently less commonly used, and there are no such types of products on the market in China. It is widely used in children and elderly patients with difficulty swallowing, emergency situations, patients with mental illness, and other fields. This is the company's "three swordsmen".

QbD Pharmaceutical retains 10% of the CRO (commissioned research and development) business as a "catfish effect" to maintain the company's vigorous research and development vitality. As a CRO background company, the company has good government relations, and experts are involved in the whole process of project initiation, R&D technical solutions, stage-by-stage R&D communication, pre-filing review of submission materials, and communication on post-filing follow-up content, to avoid approval issues. Good relationships are part of the company's project management emphasis, and professionalization, scientificization, and channelization are important guarantees for the company's development.